Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:09 AM ET 10-Q
Financial Results Aviat Networks, Inc. AVNW

Aviat Networks Q1 2026 Results: Net Loss of $2.81M

For the three months ended October 2, 2026, Aviat Networks reported a net loss of $2.8 million on total revenues of $102.0 million, a decrease from the $107.3 million in revenue and $0.2 million in net income reported in the prior year period. The decline was driven by lower product and service sales and increased cost of revenues relative to sales, resulting in a gross profit margin decrease from 33.2% to 29.6%.

Key figure
Net loss $2.81M
8:08 AM ET 8-K
Financial Results Corbus Pharmaceuticals Holdings, Inc. CRBP

Corbus Pharmaceuticals Holdings Financial Results

Corbus Pharmaceuticals reported Q3 2026 financial results and provided updates on its clinical pipeline, including the initiation of the TEMPO-1 registrational study for sutantatug envedotin in oropharyngeal cancer. The company also reported positive topline data from its CANYON-1 Phase 1b obesity study, showing 5% mean weight loss at 12 weeks for its CB1 inverse agonist CRB-913. Corbus ended the quarter with $145.6 million in cash and cash equivalents, providing a projected runway into Q3 2027.

“The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus

“For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
8:07 AM ET 8-K
Financial Results TriSalus Life Sciences, Inc. TLSI

TriSalus Life Sciences Financial Results

TriSalus Life Sciences reported Q3 2026 revenue of $12.9 million, representing 11.3% year-over-year growth driven by increased TriNav unit sales. The company revised its full-year 2026 revenue guidance to a range of $46 million to $48 million and highlighted recent FDA clearance for its TriNav Advance system.

“The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-over-year growth and received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician’s choice.”

Mary Szela, President and Chief Executive Officer

“Looking ahead, we believe we are well positioned for 2027. We more than doubled our commercial footprint over the first half of the year, and although our team productivity has ramped slightly slower than anticipated, our representatives continue to educate and drive further TriNav utilization as they build and strengthen relationships with interventional radiologists.”

Mary Szela, President and Chief Executive Officer
8:06 AM ET 8-K
Business Update Coursera, Inc. COUR

Coursera Business Update

Coursera committed to a workforce reduction plan affecting approximately 10% of its global workforce to align its cost structure following its merger with Udemy. The company expects to incur $14 million to $17 million in cash expenditures for severance and benefits, primarily during Q4 2026 and the first half of 2027. This action is part of broader integration and synergy initiatives related to the Udemy combination.

8:06 AM ET 8-K
Investor Presentation Turn Therapeutics Inc. TTRX

Turn Therapeutics Investor Presentation

Turn Therapeutics Inc. released an updated corporate investor presentation on November 10, 2026. The presentation provides a strategic overview of the company's operations and its PermaFusion technology platform. The filing was made under Item 7.01 to provide current information to the investment community.

8:06 AM ET 8-K
Capital Raise PDS Biotechnology Corp PDSB

PDS Biotechnology Capital Raise of $3.9M

NantWorks exercised outstanding common stock warrants to purchase 17,699,115 shares of PDS Biotechnology at an exercise price of $0.22 per share. The transaction generated approximately $3.9 million in gross proceeds for the company. PDS Biotech intends to use the funds to advance its PDS0301 program toward a Phase 3 trial in metastatic colorectal cancer and for general corporate purposes.

Value
$3.9M
Counterparty
NantWorks
8:05 AM ET 8-K
Financial Results Aviat Networks, Inc. AVNW

Aviat Networks Financial Results

Aviat Networks reported fiscal 2027 first quarter results with total revenues of $102.0 million, a 5% decrease year-over-year. Despite the revenue dip, the company achieved record first-quarter bookings of over $150 million, resulting in a book-to-bill ratio of 1.5. The company reported a GAAP net loss of $2.8 million but maintained a non-GAAP net income of $1.5 million.

Term
Q1 2027
8:05 AM ET 8-K
Financial Results Jerash Holdings (US), Inc. JRSH

Jerash Holdings Financial Results

Jerash Holdings reported fiscal 2027 second quarter revenue of $50.3 million, a 19.8% increase year-over-year, driven by higher shipments to U.S. customers. Net income rose significantly to $2.2 million compared to $479,000 in the prior-year period, aided by automation-related efficiency gains and disciplined cost controls. The company issued Q3 revenue guidance of $49 million to $51 million and noted that production facilities are fully booked through June 2027.

Term
Q2 2027

“We delivered a strong quarter of performance, achieving meaningful growth in both revenue and profitability. Over the past several months, we have navigated logistics challenges across the Middle East, including higher import transportation costs driven by regional shipping disruptions and ongoing uncertainty. Despite these headwinds, we expanded margins through strategic early purchases of raw materials, disciplined cost controls, reduced waste, and enhanced operational efficiencies through automation initiatives.”

Sam Choi, Jerash’s chief executive officer

“Our production facilities are fully booked through June 2027, and order in-flow remains strong. To support continued growth and capitalize on new business opportunities, we are actively seeking ways to expand capacity. Renovations at our most recently acquired facility, along with the construction of a third satellite factory supported by the Jordanian government, are expected to be completed by September 2027. Together, these projects are anticipated to increase our production capacity by approximately 15-20 percent, positioning us to meet growing customer demand and support Jerash’s long-term growth objectives.”

Sam Choi, Jerash’s chief executive officer
8:03 AM ET 8-K
Financial Results Tyra Biosciences, Inc. TYRA

Tyra Biosciences Financial Results

Tyra Biosciences reported third quarter 2026 financial results, highlighting a cash position of $700.5 million following a $400 million financing. The company is advancing its '3x3 strategy' for dabogratinib, including positive initial Phase 2 results in NMIBC and preparations for Phase 3 development.

“2026 has been a defining year for TYRA. With the initial results from SURF302 in the ablative setting, we believe dabogratinib has the potential to be the first oral FGFR3-selective inhibitor in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), reinforcing our conviction in the potential of precision FGFR3 inhibition to fundamentally change the treatment paradigm for patients.”

Todd Harris, PhD, President and Chief Executive Officer

“With a strengthened balance sheet following our $400 million financing, TYRA is entering its next phase of growth from a position of strength. We now have the financial resources to advance our dabogratinib 3x3 strategy through late-stage clinical development.”

Todd Harris, PhD, President and Chief Executive Officer
8:02 AM ET 8-K
Financial Results Co-Diagnostics, Inc. CODX

Co-Diagnostics Financial Results

Co-Diagnostics reported Q3 2026 financial results, highlighting a 12% year-over-year reduction in operating expenses and the submission of a 510(k) premarket notification to the FDA for its Flu A/B & RSV test. The company also expanded its platform capabilities through a collaboration with ReadyGo Diagnostics and the launch of cloud infrastructure in India.

Term
Q3 2026
8:02 AM ET 8-K
Financial Results Coya Therapeutics, Inc. COYA

Coya Therapeutics Financial Results

Coya Therapeutics reported Q3 2026 financial results, highlighting the completion of enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS. The company ended the quarter with $35.8 million in cash, which it expects will fund operations into the second half of 2027, past the anticipated topline data readout in early Q2 2027.

Term
Q3 2026

“Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of ALS. With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.”

Arun Swaminathan, Ph.D., Chief Executive Officer of Coya Therapeutics

“Completion of the ALSTARS trial is an important milestone as we move forward in our quest for providing a potential therapy for this lethal disease. The addition of the open-label extension provides participants the opportunity to continue on COYA 302 while we continue to collect important data.”

Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya Therapeutics
8:02 AM ET 10-Q
Financial Results PMV Pharmaceuticals, Inc. PMVP

PMV Pharmaceuticals Q3 2026 Results: Net Loss of $34.4M, Loss Widens

PMV Pharmaceuticals reported a significant increase in total liabilities to $54.3 million as of September 30, 2026, primarily driven by a new $43.6 million warrant liability. The company's cash and marketable securities totaled approximately $108.5 million, while the accumulated deficit grew to $517.0 million.

Key figure
Net loss $34.4M
8:01 AM ET 8-K
Deal Termination Aptera Motors Corp SEV

Aptera Motors Deal Termination with Cantor Fitzgerald & Co.

Aptera Motors Corp. has suspended and terminated its prospectus related to an at-the-market (ATM) offering program with Cantor Fitzgerald & Co. The company stated it will not make any further sales under the Sales Agreement until a new prospectus is filed. Additionally, the company provided a preliminary financial update estimating a cash balance of approximately $9.2 million as of September 30, 2026.

Counterparty
Cantor Fitzgerald & Co.
8:01 AM ET 8-K
Stock Plan Amendment Net Power Inc. NPWR

Net Power Stock Plan Amendment

Net Power Inc. approved an amendment to stock option agreements for its President and COO, Marc Horstman, and other eligible holders under the 2023 Omnibus Incentive Plan. The amendment extends the post-termination exercise period and allows options to continue vesting following a termination of service by the company other than for cause. The change does not affect the number of shares, exercise price, or expiration date of the existing options.

8:01 AM ET 8-K
Loan & Debt Americas Carmart Inc CRMT

Americas Carmart Debt Financing Update with Silver Point Finance, LLC

America's Car-Mart entered into an agreement with Silver Point Finance and its lenders to further extend the Scheduled Termination Date of its existing limited waiver and credit agreement amendment. The extension provides temporary relief through November 12, 2026, regarding the company's obligations to maintain minimum liquidity thresholds and a minimum Collateral Coverage Ratio.

Counterparty
Silver Point Finance, LLC
Term
through Nov 12, 2026
8:01 AM ET 8-K
Clinical Trial Data PepGen Inc. PEPG

PepGen Clinical Trial Data

PepGen reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial for PGN-EDODM1 in patients with myotonic dystrophy type 1. The data demonstrated a mean splicing correction of 46.5%, the highest reported to date in a multiple dose study, alongside functional improvements and a generally well-tolerated safety profile.

“The positive 10 mg/kg cohort results we announced today were made possible by our team’s focused execution. We are very confident in PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, and our company ended the quarter in a strong position to advance the program to the third and highest dose cohort, which is fully enrolled.”

James McArthur, Ph.D., President and Chief Executive Officer
8:01 AM ET 10-Q
Financial Results Atossa Therapeutics, Inc. ATOS

Atossa Therapeutics Q3 2026 Results: Net Loss of $5.64M, Loss Narrows

Atossa Therapeutics reported a net loss of $23.7 million for the nine months ended September 30, 2026, compared to $23.8 million in the prior year period. The company's cash position decreased significantly to $20.6 million, leading management to express substantial doubt about its ability to continue as a going concern without additional capital.

Key figure
Net loss $5.64M
8:00 AM ET 8-K
Partnership AST SpaceMobile, Inc. ASTS

AST SpaceMobile Partnership with Rakuten Group, Inc. Worth $1B

AST SpaceMobile and Rakuten Group have established a joint venture named Rakuten AST, Inc. to build a direct-to-device satellite communications network in Japan. The project is supported by approximately $1 billion (148 billion yen) in funding from Japan's Ministry of Internal Affairs and Communications (MIC) to deploy a sovereign mid-band satellite constellation. AST SpaceMobile will supply the satellites for the network, which aims to commence domestic operations by March 2029.

Value
$1B
Counterparty
Rakuten Group, Inc.
Term
3 years
8:00 AM ET 8-K
Shareholder Meeting Alliance Entertainment Holding Corp AENT

Alliance Entertainment Holding Shareholder Meeting

Alliance Entertainment Holding Corporation held its 2026 Annual Meeting of Stockholders on November 5, 2026. Stockholders elected Bruce Ogilvie and Jeffrey Walker as Class III directors and approved, on a non-binding advisory basis, executive compensation and a three-year frequency for future advisory votes on executive compensation.

8:00 AM ET 8-K
Financial Results PMV Pharmaceuticals, Inc. PMVP

PMV Pharmaceuticals Financial Results

PMV Pharmaceuticals reported a net loss of $34.4 million for the third quarter of 2026, primarily driven by a non-cash loss related to warrant liabilities. The company ended the period with $108.5 million in cash, bolstered by a $50 million public offering in August, which is expected to fund operations into early 2028. Key clinical progress includes the completion of enrollment for the rezatapopt Phase 2 ovarian cancer cohort with an NDA submission planned for Q1 2027.

Term
Q3 2026

“The updated monotherapy interim data demonstrate the potential for rezatapopt to address a significant unmet medical need. The completed $50 million public offering also positions us well to submit an NDA in the first quarter of 2027 seeking accelerated approval for treatment of platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation.”

David Mack, Ph.D., President and Chief Executive Officer
7:56 AM ET 10-Q
Financial Results Lion Copper Corp. LCU

Lion Copper Q3 2026 Results: Turns Profitable, Net Income $281K

Lion Copper Corp. reported a net loss of $10.2 million for the nine months ended September 30, 2026, though it achieved a small net income of $0.3 million in the third quarter. The company's cash position significantly improved to $21.2 million following funding activities related to the Nuton LLC earn-in agreement, though management continues to express substantial doubt about the company's ability to continue as a going concern.

Key figure
Net income $281K
7:53 AM ET 10-Q
Financial Results Paysign, Inc. PAYS

Paysign Q3 2026 Results: Net Income $6.74M, Up 204.1% YoY

Paysign, Inc. reported significant growth for the nine months ended September 30, 2026, with total revenues increasing to $87.1 million compared to $59.3 million in the prior year, driven largely by a doubling of Pharma industry revenue. Net income for the nine-month period rose to $18.9 million, up from $6.2 million in 2025, reflecting improved operating leverage and higher interest income.

Key figure
Net income $6.74M · +204.1% YoY
7:52 AM ET Form 4
Insider Buying Matador Resources Co MTDR

Matador Resources Insider Monika U. Ehrman Buys $17K of Stock

Monika U. Ehrman bought 339 shares of Matador Resources Co at $50.10 a share, worth $17K in total on Nov 9, 2026. Shares held after the trade: 45,806 (+0.7%).

Value
$17K
Shares
339
Price
$50.10
Holding change
+0.7%
Trade date
Nov 9, 2026
7:51 AM ET 8-K
Financial Results Alliance Laundry Holdings Inc. ALH

Alliance Laundry Holdings Financial Results

Alliance Laundry Holdings reported Q3 2026 net revenues of $461 million, a 5% increase year-over-year driven by volume and pricing benefits in North America. The company raised its full-year Adjusted EBITDA growth guidance to approximately 10% and reduced net leverage to 2.25x following $45 million in debt repayment.

Term
Q3 2026

“Our third quarter results reflect our deep commitment to customers and the strength, resilience and non-discretionary nature of our business model. We continue to invest in our business by expanding our connected equipment platform, deepening our distributor partnerships, and supporting the businesses, operators and people who count on our products every day.”

Michael Schoeb, CEO of Alliance
7:45 AM ET Form 4
Insider Selling Agco Corp AGCO

Agco SVP GM Fendt/Valtra Torsten Rudolf Willi Dehner Sells $3.05M of Stock

Torsten Rudolf Willi Dehner, SVP GM Fendt/Valtra, sold 27,393 shares of Agco Corp at $110.00 to $112.50 a share (average $111.37) in 2 transactions, worth $3.05M in total between Nov 6, 2026 and Nov 9, 2026. Shares held after the trade: 19,589 (-43.4%).

Value
$3.05M
Shares
27,393
Average price
$111.37
Role
SVP GM Fendt/Valtra
Holding change
-43.4%
Trade date
Nov 6, 2026 to Nov 9, 2026
7:45 AM ET 8-K
Financial Results Hive Digital Technologies Ltd. HIVE

Hive Digital Technologies Financial Results

HIVE Digital Technologies reported Q2 fiscal 2027 revenue of $84.9 million, driven by a 70% year-over-year increase in AI GPU (HPC) revenue to $8.8 million. Despite stable revenue, the company reported a GAAP net loss of $78.7 million due to significant non-cash charges, including $54.9 million in depreciation and a $31.2 million impairment on mining equipment.

Term
Q2 2027

“Our digital infrastructure platform combines established Bitcoin mining operations with a growing AI computing business. Revenue was broadly stable year over year despite a 27% decline in Bitcoin prices, while HPC revenue increased more than 70%.”

Frank Holmes, Co-Founder and Executive Chairman
7:43 AM ET Form 4
Insider Buying Crh Public Ltd Co CRH

Crh Public Ltd Insider Richard H. Fearon Buys $570K of Stock

Richard H. Fearon bought 6,000 shares of Crh Public Ltd Co at $94.95 a share, worth $570K in total on Nov 6, 2026. Shares held after the trade: 150,842 (+4.1%).

Value
$570K
Shares
6,000
Price
$94.95
Holding change
+4.1%
Trade date
Nov 6, 2026
7:42 AM ET 8-K
Financial Results Kalaris Therapeutics, Inc. KLRS

Kalaris Therapeutics Financial Results

Kalaris Therapeutics reported third quarter 2026 financial results, ending the period with $82.9 million in cash and marketable securities. The company announced a delay in its Phase 1b/2 study of TH103 for nAMD due to a manufacturing supply interruption, with preliminary data now expected in the second half of 2027. Despite the delay, the company successfully completed a technology transfer to a commercial-scale manufacturer and extended its cash runway into 2028.

Term
Q3 2026

“Kalaris made meaningful progress in the third quarter. We continue to enroll and dose nAMD patients in the ongoing Phase 1b/2 study. In addition to progressing the clinical trial, we have successfully completed the tech transfer to a new commercial-scale manufacturer, with initial test batches achieving the target specifications. Given the paramount importance of ensuring critical quality attributes at the scale required for Phase 3 and commercial supply, this was a significant accomplishment in Q3 and strengthens our confidence in our future clinical supply.”

Andrew Oxtoby, Chief Executive Officer
7:42 AM ET 8-K
Clinical Trial Data Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in patients with chronic hepatitis delta virus (HDV). The study showed that 59% of patients on the 300 mg weekly dose achieved the combined endpoint of virologic response and ALT normalization compared to 0% in the delayed-treatment arm. This data, alongside results from the AZURE-1 study, will form the basis of the company's U.S. registration package for brelovitug.

7:41 AM ET 10-Q
Financial Results Xilio Therapeutics, Inc. XLO

Xilio Therapeutics Q3 2026 Results: Net Loss of $5.95M, Loss Narrows

Xilio Therapeutics reported 7,063,982 shares of common stock outstanding as of November 6, 2026. The company highlights its reliance on strategic collaborations with AbbVie and Gilead, and notes potential gross proceeds of $36.2 million in Q4 2026 from the exercise of Series C warrants.

Key figure
Net loss $5.95M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.